Actelion Awards Grants to 2019 ENTELLIGENCE™ Young Investigators for Research in Pulmonary Vascular Disease, Dallas, TX – May 20, 2019:

Actelion Pharmaceuticals US, Inc. and the ENTELLIGENCE Steering Committee recognized four young researchers and their mentors this year for their efforts in advancing research in pulmonary vascular disease. Each researcher will receive a 12-month mentored grant of up to $100,000, funded through the Actelion-supported ENTELLIGENCE program. The announcement was made at a recent award luncheon held in Dallas, TX during the time of the American Thoracic Society’s annual meeting. The recipients of the 2019 awards gave an overview of their proposed work during the luncheon.

“Entering our 15th year of the ENTELLIGENCE Young Investigator Program, the ENTELLIGENCE Steering Committee members are proud to award four new innovative grants to promising young investigators in the field of pulmonary vascular disease. Each year, very high-quality research proposals come before us. And each year, owing to the high caliber of these proposals, the decisions for funding can be extremely challenging,” said Ronald J. Oudiz, MD, ENTELLIGENCE Steering Committee Chairman and Director of the Liu Center for Pulmonary Hypertension at the LA Biomedical Research Institute at Harbor-UCLA Medical Center.

At the annual ENTELLIGENCE luncheon during ATS, Janssen North America’s Global Chief Technology Officer for Pulmonary Hypertension, Charles R. Bridges, MD, ScD, delivered an inspirational speech to kick off the award ceremony. As has been at past award luncheons, many prior ENTELLIGENCE awardees and mentors were in attendance and were proudly recognized. Many of the ENTELLIGENCE prior awardees have gone on to publish their works in various journals and have become more senior investigators in the field of pulmonary vascular disease. “The ENTELLIGENCE Steering Committee is thrilled with the success of the program thus far. So much exciting research has come before us over the years, we couldn’t be more pleased,” said Dr. Oudiz. “For the past 14 award cycles, ENTELLIGENCE, with more than $5.8 million in funding, has supported innovative basic, translational, and clinical research that has now fostered the development of 67 young investigators’ careers in pulmonary vascular disease. During this time, the awardees’ research findings have been published in numerous peer-reviewed journals, and with the momentum of their ENTELLIGENCE awards, many have obtained external funding to continue their research,” Oudiz said.

“We are thrilled to honor and celebrate these bright young investigators and the dedicated mentors who guided them to excel in their research,” said Gary Palmer, MD, MBA, Senior Vice President, Medical, Actelion Pharmaceuticals US, Inc. “The four individuals awarded this year have made significant strides in pulmonary hypertension research and are at the forefront of advancing care for people with PAH. We congratulate the awardees and look forward to their continued contributions to the future of pulmonary hypertension research.”

Attendees included Charles R. Bridges, MD, ScD; and from Actelion Pharmaceuticals US, Inc.: Serge Messerlian, President, Gary Palmer, MD, MBA, Senior Vice President, and Peter Agron, PhD, Associate Director. Additional leaders and researchers in the field of pulmonary vascular disease included Brad Wong, President of the Pulmonary Hypertension Association.

The 2019 award winners, co-investigator, their mentors, and the supported projects are:

**Mark Dodson, MD, PhD**

**Mentors:** Gregory Elliott, MD, and Lisa Cannon-Albright, PhD  
**Institution:** Intermountain Medical Center, Department of Medicine, Pulmonary and Critical Care  
**Title:** Identifying Genetic Risk Factors for Chronic Thromboembolic Pulmonary Hypertension

**Jonathan Edwards, MD**

**Mentors:** Zoltan Arany, MD, and Laura Mercer-Rosa, MD  
**Institution:** Children’s Hospital of Philadelphia, Department of Pediatrics, Division of Cardiology  
**Title:** Investigating Altered Right Ventricular Myocardial Gene Expression and Biomarkers Patterns Associated with Adaptive and Maladaptive Remodeling in Diverse Human Models
Andrea Frump, PhD  
Co-Investigator: Mark Geraci, MD  
Mentors: Tim Lahm, MD, and Micheala Aldred, PhD  
Institution: Indiana University School of Medicine  
Indianapolis, IN  
Title: Identification of the Apelin-mediated Transcriptome in Right Ventricular Failure using Single Cell RNA-Seq

Victor Tseng, MD  
Mentors: C. Michael Hart, MD, and Eva Grayck, MD  
Institution: Emory University, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine  
Atlanta, GA  
Title: Hyaluronan Drives Pathologic Vascular Metabolism in Pulmonary Hypertension

About ENTELLIGENCE  
The ENTELLIGENCE program was established by Actelion in 2005 to support basic science, translational, and clinical research related to pulmonary vascular disease. The program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research in pulmonary hypertension (PH) related to expanding our knowledge of the pathways involved in pulmonary vascular disease. ENTELLIGENCE is led by a Steering Committee comprised of leaders in the field of PH.

The next ENTELLIGENCE grant award cycle begins on July 18th. For more information regarding the Young Investigator Program, please visit www.ENTELLIGENCEMD.org. For further information, please contact Medtelligence (info@medtelligence.net).

2019 Award Winners.  
From left: Mark Dodson, MD, PhD, Jonathan Edwards, MD, Victor Tseng, MD, and Andrea Frump, PhD.

2019 Award Winners and ENTELLIGENCE Steering Committee.  
From left: Harold I. Palevsky, MD, Mark Dodson, MD, PhD, Harrison W. Farber, MD, Jonathan Edwards, MD, Kurt R. Stenmark, MD, Victor Tseng, MD, Andrea Frump, PhD, Ronald J. Oudiz, MD, Program Chair, and Jaxon X-J Yuan, MD, PhD. Not shown: Mardi Gomberg-Maitland, MD, MSc, Maureen D. Mayes, MD, MPH, Evangelos D. Michelakis, MD, and Richard M. Silver, MD.